Cullinan Therapeutics Starts NDA Submission for Zipalertinib
Cullinan Therapeutics has initiated a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy. This submission targets first-line treatment for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, utilizing the FDA's Real-Time Oncology Review (RTOR) program.
Cullinan Therapeutics initiated an NDA submission to the FDA for zipalertinib plus platinum-based chemotherapy in first-line EGFR exon 20 insertion NSCLC under the RTOR program.Key Highlights:Original SEC Filing: Cullinan Therapeutics, Inc. [ CGEM ] - 8-K - Oct. 01, 2026This is an AI-powered summar…